Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Slides:



Advertisements
Similar presentations
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,
Advertisements

1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.
A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Prognostication of survival using cardiac troponins and N- terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing.
Controversies in multiple myeloma: Evidence-based update
by Angela Dispenzieri, A. Keith Stewart, Asher Chanan-Khan, S
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and
by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome by Anita D'Souza, Suzanne.
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
by Rafael Fonseca, Richard J. Bailey, Gregory J. Ahmann, S
P16 INK4a andp15 INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance by Gaëlle Guillerm, Emmanuel Gyan, Darius.
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
How I treat elderly patients with myeloma
Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara.
The role of complete response in multiple myeloma
by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu
A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.
Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.
Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma  Ravi Vij, Shaji Kumar, Mei-Jie Zhang,
Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,
Solitary plasmacytoma of bone and asymptomatic multiple myeloma
Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.
Imatinib for refractory chronic graft-versus-host disease with fibrotic features by Attilio Olivieri, Franco Locatelli, Marco Zecca, Adele Sanna, Michele.
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma by Mohammed A. Aljama, M. Hasib Sidiqi, Arjun.
by Michael F. Leahy, and J. Harvey Turner
Natural course of HTLV-1 carriers with monoclonal proliferation of T lymphocytes (“pre-ATL”) in a 20-year follow-up study by Yoshitaka Imaizumi, Masako.
Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma  Dan T. Vogl, Tao Wang, Waleska S. Pérez,
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:
by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,
Volume 73, Issue 11, Pages (June 2008)
Volume 94, Issue 5, (November 2018)
Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Ayman.
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.
Overall survival by SCT versus observation in first complete remission
Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation  Shaji Kumar, Waleska S. Pérez, Mei-Jie.
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines  Stephen.
Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition  Terry M. Therneau, PhD,
Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,
Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.
Treatment versus Transplant for Challenging Hematologic Disorders
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis by Mohammed A. Aljama, M. Hasib Sidiqi,
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
by Robert A. Kyle, and S. Vincent Rajkumar
Suggested algorithm for bone marrow biopsy and skeletal imaging in patients with monoclonal gammopathy of undetermined significance. #Mayo Clinic Risk.
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia
Two major molecular subgroups within PTCL-NOS with biological and overall survival differences. Two major molecular subgroups within PTCL-NOS with biological.
Balancing bleeding in brain metastases
Cold agglutinin disease
Presentation transcript:

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K. Wadhera, Robert A. Kyle, Dirk R. Larson, Angela Dispenzieri, Shaji Kumar, Hillard M. Lazarus, and S. Vincent Rajkumar Blood Volume 118(11):2985-2987 September 15, 2011 ©2011 by American Society of Hematology

OS among all patients. OS among all patients. Median overall survival was 73 months in patients with secondary MGUS versus 38 months in the rest of the cohort (P < .001). Cum. survival indicates cumulative survival. Rishi K. Wadhera et al. Blood 2011;118:2985-2987 ©2011 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.